Aclaris Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ACRS Nasdaq 2830 www.aclaristx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aclaris Therapeutics, Inc.

Aclaris Therapeutics to Participate in Two March Healthcare Conferences - Mar 4th, 2025 12:00 pm
This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Mar 4th, 2025 11:46 am
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Mar 4th, 2025 11:21 am
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates - Feb 27th, 2025 1:20 pm
Aclaris: Q4 Earnings Snapshot - Feb 27th, 2025 12:21 pm
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - Feb 27th, 2025 11:59 am
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - Feb 12th, 2025 11:50 am
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - Jan 30th, 2025 9:01 pm
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 6th, 2025 9:30 pm
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - Nov 26th, 2024 9:30 pm
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch - Nov 22nd, 2024 12:04 am
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies - Nov 20th, 2024 10:11 am
Aclaris Therapeutics upgraded to Buy from Neutral at BTIG - Nov 20th, 2024 2:30 am
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments - Nov 19th, 2024 8:27 pm
Aclaris Therapeutics secures global rights to Biosion’s antibodies - Nov 19th, 2024 4:00 pm
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs - Nov 19th, 2024 2:19 pm
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets - Nov 18th, 2024 1:50 pm
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - Nov 18th, 2024 1:10 pm
Aclaris Therapeutics Announces $80 Million Private Placement - Nov 18th, 2024 1:10 pm
News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts - Nov 12th, 2024 11:14 am